Relaxation induced by the nitric oxide donor and COX inhibitor (NCX2121) in the renal hypertensive rat aorta.

Author(s)

Tiago Dal Cin de Paula

• Document type: Master's Dissertation
• Press: Ribeirão Preto.
• Institution: Universidade de São Paulo (USP). Faculdade de Ciências Farmacêuticas de Ribeirão Preto (PCARP/BC)
• Defense date: 2014-03-11

Examining board members

Lusiane Maria Bendhack; Rita de Cassia Aleixo Tostes Passaglia; Gerson Jhonatan Rodrigues

• Advisor: Lusiane Maria Bendhack

Abstract

The vascular endothelium plays multiple roles on the tone control by the production and/or release of contractile factors (EDCFs) and relaxing factors (EDRFs). There is an imbalance between EDCFs and EDRFs in hypertension that is defined by endothelial dysfunction. In accordance to several authors, these alterations are due to increased production of reactive oxygen species (ROS). The ROS can affect the nitric oxide (NO) signaling, production and bioavailability that is the major EDRF. ROS can also increase the levels of prostaglandins and thromboxane (TX) that are EDCFs products of COX. The main target for NO is the activation of soluble guanylyl-cyclase (sGC) in the vascular smooth muscle cells causing vasorelaxation. In renal hypertensive rats (2K-1C), there is an increased production of ROS by NADH-NADPH-oxidase in the rat aorta endothelial cells. In the present study we used the compound NCX2121, in which chemical structure there is a NO donor and a non-selective COX inhibitor indomethacin. This study aimed to pharmacologically characterize the NCX2121 relaxing effect in 2K-1C rat aorta, and to investigate the contribution of the endothelial factors and ROS for this response. We verified that the relaxation-induced by NCX2121 was impaired by the endothelium removal and NO-synthase (NOS) inhibition. The relaxation induced by NCX2121 is due to NO, since sGC inhibition by ODQ completely abolished its effect in denuded endothelium 2K-1C rat aorta. However, in intact endothelium normotensive 2K rat aorta, the relaxing effect of NCX2121 was only partially inhibited whereas in 2K-1C it was not changed. NCX2121 did not change the phosphorylation sites of activation or inhibition of NOS. NO was not detected by amperometry in the organ bath during the relaxation induced by NCX2121, but it was measured in the cell cytoplasm by confocal microscopy. The vasorelaxation was inhibited by ROS, and NCX2121 decreased the ROS in isolated endothelial cells. NCX2121 reduced TX in 2K and 2K-1C rat aortas. Therefore, our results indicate that the compound NCX2121 induces relaxation by intracellular NO release and COX inhibition by the reduced production of contractile prostanoids such as TX. The compound NCX2121 does not modulate NOS, but it decreases ROS in the endothelial cells. (AU)

• FAPESP's process: 12/05030-2 - Characterization of the nitric oxide donor compound and inhibitor of COX NCX 2121 in the hypertensive rat aorta
• Grantee: Tiago Dal-Cin de Paula
• Support Opportunities: Scholarships in Brazil - Master